Why Tapestry Stock Is Cooling Off Despite Coach’s Hot Streak
Tapestry slips as BofA downgrades on margin concerns and tempered FY26 growth outlook, despite continued strength at Coach. Latest Ratings for TPR Date Firm Action From To Feb 2022 Barclays Maintains Overweight Jan 2022 Citigroup Upgrades Neutral Buy Nov 2021 Argus Research Upgrades Hold Buy View More Analyst Ratings for TPR View the Latest Analyst…
Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout
Bausch Health will acquire DURECT and larsucosterol, aiming for FDA approval of a first treatment for alcoholic hepatitis via Phase 3 trials. read more
American Tower Sees Slightly Weaker US Growth As International Performance Strengthens
American Tower slips as steady Q2 results and 2025 guidance spark a cautious, wait-and-see investor stance. Latest Ratings for AMT Date Firm Action From To Mar 2022 Wells Fargo Maintains Overweight Mar 2022 Barclays Maintains Overweight Mar 2022 Credit Suisse Maintains Outperform View More Analyst Ratings for AMT View the Latest Analyst Ratings read more